Summit, NJ, United States of America

Michael McNevin

This inventor holds 1 USPTO granted patent and 4 published patent applications and 1 EPO patent. Top assignee: Portola Pharmaceuticals, Inc.. Active years: 2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael McNevin. Retrieved from https://idiyas.com/inventor/michael-mcnevin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 9.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Michael McNevin: Innovator in Pharmaceutical Chemistry

Introduction

Michael McNevin is a notable inventor based in Summit, NJ (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative compounds.

Latest Patents

Michael McNevin holds 1 patent for his work on crystalline forms of a factor Xa inhibitor. His patent, titled "Crystalline forms of a maleate salt of betrixaban," provides compositions and methods of preparation or use thereof. This invention is crucial in the ongoing efforts to develop effective anticoagulant therapies.

Career Highlights

Michael is currently employed at Portola Pharmaceuticals, Inc., where he continues to advance his research in pharmaceutical innovations. His work has been instrumental in the development of new therapeutic agents that can improve patient outcomes.

Collaborations

Throughout his career, Michael has collaborated with talented professionals, including Vincent R Capodanno and Liam Corcoran. These collaborations have fostered a productive environment for innovation and research.

Conclusion

Michael McNevin's contributions to pharmaceutical chemistry exemplify the impact of innovative thinking in medicine. His work continues to influence the development of new treatments that can benefit patients worldwide.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…